Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.81 |
| ▸ | HTR2A | P28223 | 6/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SCN1A | P35498 | 3/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.56 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | THPO | P40225 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolpropamine SCHEMBL4193587 | 0.98 | HRH1 (0.78) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| Tolpropamine SCHEMBL1651656 | 0.96 | HRH1 (0.75) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL1802493 | 0.90 | HRH1 (1.00) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11383046 | 0.88 | HRH1 (0.95) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL29723649 | 0.83 | CNR1 (0.56) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL10778672 | 0.83 | HTR2A (0.78) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL14198390 | 0.81 | CHRM2 (0.83) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL11382183 | 0.80 | HRH1 (0.72) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL29101424 | 0.79 | HRH1 (0.78) | HRH1HTR2ACHRM2SLC6A2SLC6A4 | |
| SCHEMBL6546820 | 0.78 | CNR1 (0.51) | HRH1HTR2ACHRM2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 610 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112194839-A | High-strength PE cast film and preparation method thereof | 中天（中国）工业有限公司 | 2021-01-08 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| CN-107049932-A | Small molecule drug in-situ phase change gel sustained release system and preparation method thereof | 四川大学 | 2017-08-18 | — | — | CN | claimed |
| US-20150216898-A1 | COMPOSITION FOR TREATING PSORIASIS | PSORIASIS+CREAMS SWENDEN AB (SE) | 2015-08-06 | — | — | US | claimed |
| CN-104602697-A | Composition for treating psoriasis | PSORIASIS & CREAMS SWEDEN AB | 2015-05-06 | — | — | CN | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| EP-2705847-B1 | Composition for treating psoriasis | PSORIASIS & CREAMS SWEDEN AB (SE) | 2014-07-02 | — | — | EP | claimed |
| EP-1919450-B1 | ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | MEDA AB (SE) | 2014-06-11 | — | — | EP | claimed |
| WO-2014037343-A1 | COMPOSITION FOR TREATING PSORIASIS | PSORIASIS+CREAMS SWEDEN AB (SE) | 2014-03-13 | — | — | WO | claimed |
| US-20140065203-A1 | ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2014-03-06 | — | — | US | claimed |
| CN-102526753-B | In-situ phase change gel slow release system taking phospholipid as substrate and preparation method thereof | CHENGDU SHICHUANG BIOMEDICAL TECHNOLOGY CO LTD | 2014-01-22 | — | — | CN | claimed |
| US-20090324699-A1 | Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders | MEDA AB (SE) | 2009-12-31 | — | — | US | claimed |
| CN-101257891-A | Liposome composition comprising an antihistamine and a corticosteroid and its use for the preparation of a medicament for the treatment of rhinitis and related disorders | BIOLIPOX AB (SE) | 2008-09-03 | — | — | CN | claimed |
| EP-1919450-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | Biolipox AB (SE) | 2008-05-14 | — | — | EP | claimed |
| WO-2007026151-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2007-03-08 | — | — | WO | claimed |
| US-20040223946-A1 | Adhesive treatment for insect and related bites | CLOSURE MEDICAL CORPORATION | 2004-11-11 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040223946-A1 | Adhesive treatment for insect and related bites | CUTA, FGB, ICAM1 | HRH1 278/4885HTR2A 2375/4885CHRM2 2040/4885 |
| US-20140065203-A1 | ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | HRH1, HRH4, HRH3 | HRH1 1/4885HTR2A 178/4885CHRM2 104/4885 |
| US-20090324699-A1 | Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders | LIPA, HRH1, HRH2 | HRH1 2/4885HTR2A 156/4885CHRM2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.